Edgar Filing: Ultragenyx Pharmaceutical Inc.

Date: June 16, 2016

Ultragenyx Pharmaceutical Inc.

/s/ Shalini Sharp

Shalini Sharp

Senior Vice President, Chief Financial Officer

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 10, 2016

Ultragenyx Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36276

27-2546083

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

60 Leveroni Court,

Novato, California

94949

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (415) 483-8800

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On June 10, 2016, Sunil Agarwal gave notice of his intention to resign as Executive Vice President and Chief Medical Officer of Ultragenyx Pharmaceutical Inc. (the “Company”) to pursue an alternative career path. Dr. Agarwal’s resignation will be effective as of August 18, 2016. Following Dr. Agarwal’s departure, Emil Kakkis, the Company’s Chief Executive Officer, will directly manage the development leadership team to advance the Company’s development programs.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.